Marker Therapeutics, Inc.
  • About
    • Company Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100
    • Expanded Access Program
  • Investors
    • Overview
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
  • News
    • Press Releases
    • Media Coverage
    • Events
    • Press Kit
    • Email Alerts
  • Contact
  • Careers
Marker Therapeutics, Inc.
Marker Therapeutics, Inc.
  • About
    • Company Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100
    • Expanded Access Program
  • Investors
    • Overview
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
  • News
    • Press Releases
    • Media Coverage
    • Events
    • Press Kit
    • Email Alerts
  • Contact
  • Careers

+1 (713) 400-6400

Email Us

  • LinkedIn
  • Facebook
  • Twitter

3200 Southwest Fwy #2240 Phoenix Tower
Houston, TX 77027

© 2021 Marker Therapeutics, Inc.

TapImmune’s Approach to a Her-2/Neu Therapeutic Vaccine

September 25, 2016

Mark Reddish, Vice President Development
https://www.markertherapeutics.com/wp-content/uploads/2014/12/White-Paper-Immunotherapy-in-the-Age-of-Vaccinomics-Mark-Reddish-TapImmune-Inc.pdf

Categories
  • Science Publications
Previous Post Next Post

Recent Posts

  • Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
  • Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
  • Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
  • Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
  • Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020

Categories

  • Press Releases
  • Media Coverage

Content by Month

  • March 2021
  • January 2021
  • November 2020
  • September 2020
  • August 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • November 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • June 2015
  • May 2015
  • March 2015
  • February 2015
  • January 2015
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • March 2014
  • February 2014
  • October 2013
  • June 2013
  • September 2007
  • July 2007
  • June 2007
  • February 2007
  • December 2005
  • September 2005
  • August 2005
  • May 2004
  • May 2000

Sign up for email alerts

Get Marker News Delivered To Your Inbox

Sign Up Today
About
  • Company Overview
  • Company Management
  • Board of Directors
  • Scientific Advisory Board
  • Contact Us
  • Careers
Technology
  • Multi Antigen Targeted T Cell Therapies
  • T Cell Vaccines
  • PolyStart™
Clinical Studies
  • Pipeline
  • MultiTAA T Cell Therapy
  • TPIV200 Clinical Trials
  • TPIV100
Investors
  • Overview
  • Company Profile
  • Stock Information
  • SEC Filings
  • Analyst Coverage
  • Corporate Governance
  • Shareholder FAQ
  • Downloads
Downloads
  • Fact Sheet
  • ASBMT 2019 Presentations
Follow Us
  • LinkedIn
  • Facebook
  • Twitter
  • Contact
  • Privacy
  • Disclaimer

© 2021 Marker Therapeutics, Inc.